Targeting the ubiquitin-proteasome pathway with inorganic compounds to fight cancer: a challenge for the future (Q34195083)

31 July 2017

title

Targeting the ubiquitin-proteasome pathway with inorganic compounds to fight cancer: a challenge for the future (English)

1 reference

ubiquitin-proteasome system

31 July 2017

main subject

0 references

Chiara Nardon

0 references

Lisa Dalla Via

0 references

Dolores Fregona

1 reference

31 July 2017

publication date

1 March 2012

1 reference

Future Medicinal Chemistry

31 July 2017

published in

1 reference

31 July 2017

1 reference

31 July 2017

1 reference

31 July 2017

page(s)

525-543

1 reference

Molecular machines for protein degradation

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

21 January 2018

The proteasomal system.

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Drug discovery in the ubiquitin-proteasome system.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

A soluble ATP-dependent proteolytic system responsible for the degradation of abnormal proteins in reticulocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Proteasome-dependent regulation of p21WAF1/CIP1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Ubiquitin-independent p53 proteasomal degradation.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

The roles of intracellular protein-degradation pathways in neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

20S proteasome and its inhibitors: crystallographic knowledge for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Inhibition of the ubiquitin-proteasome system by natural products for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

The three-dimensional structure of proteasomes from Thermoplasma acidophilum as determined by electron microscopy using random conical tilting

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

The persisting challenge of selective and specific proteasome inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Structure of 20S proteasome from yeast at 2.4 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Proteasome inhibitors as potential novel anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Functions of the proteasome: the lysis at the end of the tunnel

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

The ubiquitin-proteasome system as a prospective molecular target for cancer treatment and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

The role of the ubiquitination-proteasome pathway in breast cancer: applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

The ubiquitin-proteasome pathway: the complexity and myriad functions of proteins death

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

The ubiquitin-proteasome system in cardiovascular diseases-a hypothesis extended

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

The ubiquitin system, disease, and drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

The ubiquitin proteasome system in neuropathology

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

The ubiquitin-proteasome pathway: on protein death and cell life

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Targeting the ubiquitin system in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Feedback regulation of proteasome gene expression and its implications in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Metal complexes, their cellular targets and potential for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Targeting of nuclear factor-kappaB and proteasome by dithiocarbamate complexes with metals

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Novel proteasome inhibitors to overcome bortezomib resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Proteasome inhibition and its therapeutic potential in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Approval summary for bortezomib for injection in the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Inhibitors of the eukaryotic 20S proteasome core particle: a structural approach

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

The catalytic sites of 20S proteasomes and their role in subunit maturation: a mutational and crystallographic study

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

UCSF Chimera--a visualization system for exploratory research and analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Strategies for the inhibition of serine proteases

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Development and evaluation of a boronate inhibitor of gamma-glutamyl transpeptidase

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

X-ray and NMR characterization of covalent complexes of trypsin, borate, and alcohols

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Success in translational research: lessons from the development of bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

A pivotal role for Mcl-1 in Bortezomib-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Phase I study of bortezomib in refractory or relapsed acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Novel metals and metal complexes as platforms for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Mechanisms of angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Rat epigastric flap survival and VEGF expression after local copper application

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Copper-induced vascular endothelial growth factor expression and wound healing

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Inhibition of prostate cancer cellular proteasome activity by a pyrrolidine dithiocarbamate-copper complex is associated with suppression of proliferation and induction of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Pyrrolidine dithiocarbamate-zinc(II) and -copper(II) complexes induce apoptosis in tumor cells by inhibiting the proteasomal activity

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Metals in anticancer therapy: copper(II) complexes as inhibitors of the 20S proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Antitumor activity and toxicity of salts of inorganic group 3a metals: aluminum, gallium, indium, and thallium

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Gallium nitrate in the treatment of bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Treatment of patients with advanced malignant lymphoma using gallium nitrate administered as a seven-day continuous infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Gallium radiopharmaceutical chemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Effects of different transferrin forms on transferrin receptor expression, iron uptake, and cellular proliferation of human leukemic HL60 cells. Mechanisms responsible for the specific cytotoxicity of transferrin-gallium

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Targeting Iron-Dependent DNA Synthesis with Gallium and Transferrin-Gallium

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Synthesis, structure, and anticancer activity of gallium(III) complexes with asymmetric tridentate ligands: growth inhibition and apoptosis induction of cisplatin-resistant neuroblastoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Inhibition of the proteasome activity by gallium(III) complexes contributes to their anti prostate tumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Comparative activities of nickel(II) and zinc(II) complexes of asymmetric [NN'O] ligands as 26S proteasome inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Role of disease-modifying antirheumatic drugs versus cytotoxic agents in the therapy of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Gold coordination complexes as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Anticancer therapeutics that target selenoenzymes: synthesis, characterization, in vitro cytotoxicity, and thioredoxin reductase inhibition of a series of gold(I) complexes containing hydrophilic phosphine ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

The chemistry of gold drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Gold(III) porphyrins as a new class of anticancer drugs: cytotoxicity, DNA binding and induction of apoptosis in human cervix epitheloid cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Gold compounds as therapeutic agents for human diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Gold(III)-dithiocarbamato complexes induce cancer cell death triggered by thioredoxin redox system inhibition and activation of ERK pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

A novel anticancer gold(III) dithiocarbamate compound inhibits the activity of a purified 20S proteasome and 26S proteasome in human breast cancer cell cultures and xenografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

The Midas touch in cancer chemotherapy: from platinum- to gold-dithiocarbamato complexes.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Gold dithiocarbamate derivatives as potential antineoplastic agents: design, spectroscopic properties, and in vitro antitumor activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Chemistry, antiproliferative properties, tumor selectivity, and molecular mechanisms of novel gold(III) compounds for cancer treatment: a systematic study

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Gold(III) dithiocarbamate derivatives for the treatment of cancer: solution chemistry, DNA binding, and hemolytic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Antitumor activity of gold(III)-dithiocarbamato derivatives on prostate cancer cells and xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

A Screening Strategy for Metal Antitumor Agents as Exemplified by Gold(III) Complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Latest insights into the anticancer activity of gold(III)-dithiocarbamato complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Proteolysis, free radicals, and aging

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Inhibition of tumor proteasome activity by gold-dithiocarbamato complexes via both redox-dependent and -independent processes

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Antiproliferative and apoptotic effects of two new gold(III) methylsarcosinedithiocarbamate derivatives on human acute myeloid leukemia cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Effect of glutathione depletion on antitumor drug toxicity (apoptosis and necrosis) in U-937 human promonocytic cells. The role of intracellular oxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Effect of gold nanoparticle on renal cell: an implication for exposure risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Thioredoxin reductase: A target for gold compounds acting as potential anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

Reactions of gold(III) complexes with serum albumin

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FFMC.11.187

21 January 2018

Identifiers

DOI

10.4155/FMC.11.187

1 reference

31 July 2017

1 reference